<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 13)*
DIAGNOSTIC PRODUCTS CORPORATION
- --------------------------------------------------------------------------------
(Name of Issuer)
COMMON STOCK, NO PAR VALUE
- --------------------------------------------------------------------------------
(Title of Class of Securities)
252450-10-1
-----------------------------
(CUSIP Number)
*The remainder of this cover page shall be filed out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
PAGE 1
<PAGE> 2
CUSIP NO. 252450-10-1 SCHEDULE 13G
(1) NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
MARILYN ZIERING
---------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (A) [ ]
(B) [ ]
---------------------------------------------------------------------
(3) SEC USE ONLY
---------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
U.S.A.
---------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF 2,442,656
SHARES --------------------------------------------------------
BENEFICIALLY (6) SHARED VOTING POWER
OWNED BY 18,500
EACH --------------------------------------------------------
REPORTING (7) SOLE DISPOSITIVE POWER
PERSON WITH 2,442,656
--------------------------------------------------------
(8) SHARED DISPOSITIVE POWER
18,500
--------------------------------------------------------
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,461,156
---------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN
SHARES [ ]
---------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
17.94%
---------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON
IN
---------------------------------------------------------------------
PAGE 2
<PAGE> 3
Item 1(a) Name of Issuer: Diagnostic Products Corporation
Item 1(b) Address of Issuer's Principal Executive Offices:
5700 West 96th Street
Los Angeles, California 90045
Item 2(a) Name of Person Filing: Marilyn Ziering
Item 2(b) Address of Principal Office: 5700 West 96th Street
Los Angeles, CA 90045
Item 2(c) Citizenship: U.S.A.
Item 2(d) Title of Class of Securities: Common Stock
Item 2(e) CUSIP Number: 252450-10-1
Item 3 Statement filed Pursuant to Rules 13d-1(b) or 13-2(b):
Not Applicable
Item 4(a) Amount Beneficially Owned: 2,461,156 shares, including
18,500 shares owned by mother-in-law who resides in same
home (as to which shares beneficial ownership is
disclaimed).
Item 4(b) Percent of Class: 17.94%
Item 4(c) Number of shares as to which reporting person has:
(i) sole power to vote or to direct the vote: 2,442,656
(ii) shared power to vote or to direct the vote: 18,500
(iii) sole power to dispose or to direct the disposition
of: 2,442,656
(iv) shared power to dispose or to direct the disposition
of: 18,500
Item 5 Ownership of 5% or Less of Class: Not Applicable
Item 6 Ownership of More than 5% on Behalf of Another Person:
Not Applicable
Item 7 Identification and Classification of the Subsidiary which
Acquired the Security Being Reported on by the Parent
Holding Company: Not Applicable
Item 8 Identification and Classification of Members of the Group:
Not Applicable
Item 9 Notice of Dissolution of Group: Not Applicable
Item 10 Certification: Not Applicable
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: February 2, 1998 /s/ Marilyn Ziering
-----------------------------------
Marilyn Ziering
PAGE 3
